Currently, the two approved methods of biopharmaceuticals manufacturing widely used in Europe are mammalian cell culture manufacturing and microbial fermentation, but there are new opportunities, as well as challenges on the way, says market research firm Frost & Sullivan.
The high production and layout costs, bottlenecks in downstream processing, high vulnerability to microbial contamination, lengthy timescales and capacity constraints associated with these traditional manufacturing processes fuel the demand for innovative and cost-effective manufacturing alternatives such as the use of transgenic animals and plants for the production of biopharmaceuticals. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.http://www.thepharmaletter.com/file/23065/register-for-a-free-trial.html
No comments:
Post a Comment